AbbVie’s biggest deal since 2019 could land soon
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"AbbVie’s biggest deal since 2019 could land soon" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Axios, Endpoints News, Yahoo Finance and Seeking Alpha. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 133d ago.
Quick answers
Why is "AbbVie’s biggest deal since 2019 could land soon" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- AbbVie strikes $10.9B deal for Apogee Therapeutics Axios · 136d ago
- AbbVie makes $10.9B move for Apogee’s long-acting I&I drug candidates Endpoints News · 136d ago
- AbbVie strikes $10.9 billion deal for Apogee Therapeutics Yahoo Finance · 136d ago
- Apogee soars on AbbVie deal report; analysts bullish (ABBV:NYSE) Seeking Alpha · 136d ago
- AbbVie-Apogee acquisition a ‘solid fit,’ JPMorgan says Investing.com · 136d ago
- AbbVie’s biggest deal since 2019 could land soon thestreet.com · 136d ago
Topics
Related trends
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
AbbVie reports Q3 2026 sales performance aligned with analyst estimates, driven by growth in its immunology and neuroscience portfolios.
AbbVie’s next-gen Crohn’s disease combo beats Skyrizi in phase 2 trial
AbbVie presents phase 2 trial data for its next-generation Crohn's disease therapy, ABBV-466.
FDA approves once-daily Parkinson’s pill (Juvmo) built on decades of work by husband-and-wife team
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
After $10.9B exit to AbbVie, Apogee execs join Paragon to scale its R&D, company creation engine
Former Apogee executives join Paragon Labs to scale R&D following an acquisition, while Alaunos Therapeutics secures major financing.
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
Genmab releases new phase 2 data for its antibody-drug conjugate, prompting claims of superiority over rival treatments.
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease
The FDA has approved Juvmo, a first-in-class Parkinson's disease medication, validating AbbVie's $8.7 billion acquisition of Cerevel.